[6-K] Radiopharm Theranostics Ltd Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Radiopharm Theranostics Limited furnished a Form 6-K to provide investors with an announcement made on the Australian Securities Exchange. The exhibit reports that the company has reached 50% enrollment in its Phase 2b clinical trial of RAD101, indicating that half of the planned participants have now been enrolled in this study. The Form 6-K states that the attached notice is being furnished, not filed, under U.S. securities laws and will only be incorporated into other securities filings if specifically referenced.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of November 2025

Commission File Number: 001-41621

RADIOPHARM THERANOSTICS LIMITED

(Name of Registrant)

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐       No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

RADIOPHARM THERANOSTICS LIMITED

EXPLANATORY NOTE

Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on November 17, 2025 titled:

“RAD Announces 50% Enrollment in Phase 2b Trial of RAD101”

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

1

EXHIBITS

Exhibit Number		Description
99.1		RAD Announces 50% Enrollment in Phase 2b Trial of RAD101

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	RADIOPHARM THERANOSTICS LIMITED
Date: November 17, 2025	By:	/s/ Phillip Hains
		Phillip Hains
		Company Secretary

3

FAQ

What did Radiopharm Theranostics (RADX) report in this Form 6-K?

Radiopharm Theranostics reported that it furnished an Australian Securities Exchange announcement as an exhibit, highlighting that 50% enrollment has been achieved in its Phase 2b trial of RAD101.

What clinical milestone did RADX announce for RAD101?

The company disclosed that it has reached 50% enrollment in a Phase 2b clinical trial of its candidate RAD101, meaning half of the planned trial participants have been enrolled.

Is the RADX Form 6-K considered filed or furnished under U.S. securities law?

The document states that the Form 6-K, including its exhibit, is being furnished rather than filed for purposes of the Exchange Act and will not be incorporated into other securities filings unless expressly referenced.

Which exhibit is attached to the Radiopharm Theranostics (RADX) Form 6-K?

The Form 6-K includes Exhibit 99.1, titled "RAD Announces 50% Enrollment in Phase 2b Trial of RAD101", which is the public notice released on the Australian Securities Exchange.

Who signed the Radiopharm Theranostics (RADX) Form 6-K?

The report was signed on behalf of Radiopharm Theranostics Limited by Phillip Hains, who is identified as the Company Secretary.

Does the RADX Form 6-K include financial or earnings data?

No financial or earnings data are presented in this Form 6-K; it primarily furnishes an announcement about trial enrollment progress for RAD101.